Brief: Rallybio Announces Approval Of Clinical Trial Applications For Phase 2 Trial Of RLYB212 In Pregnant Women At Higher Risk Of Alloimmunization And FNAIT
29/10/2024 12:25
Oct 29 (Reuters) - Rallybio Corp RLYB.O :
* RALLYBIO ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATIONS
FOR
PHASE 2 TRIAL OF RLYB212 IN PREGNANT WOMEN AT HIGHER RISK OF
ALLOIMMUNIZATION AND FNAIT
* RALLYBIO CORP - PHASE 2 TRIAL SCREENING TO INITIATE IN 4Q
2024
Source text: ID:nBw2hVgHTa
Further company coverage: RLYB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx